Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
---|
10/14/2014 | US8858950 Delivery of pharmaceutical agents via the human insulin receptor |
10/14/2014 | US8858949 Antibodies that specifically bind to a beta oligomers and use thereof |
10/14/2014 | US8858948 Compositions and methods for the therapy and diagnosis of influenza |
10/14/2014 | US8858947 Hepatitis C antibodies and uses thereof |
10/14/2014 | US8858946 Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies |
10/14/2014 | US8858945 Three-dimensional structure of complement receptor type 2 and uses thereof |
10/14/2014 | US8858944 Treatment drug for autoimmune diseases and allergic diseases |
10/14/2014 | US8858943 Antigen binding proteins |
10/14/2014 | US8858942 Antibodies directed to ERBB2 |
10/14/2014 | US8858941 VEGF/DLL4 binding agents and uses thereof |
10/14/2014 | US8858938 Human monoclonal antibodies against Hendra and Nipah viruses |
10/14/2014 | US8858937 Optimized Fc variants and methods for their generation |
10/14/2014 | US8858936 Compositions with hematopoietic and immune activity |
10/14/2014 | US8858935 Compositions and methods for increasing the stability of antibodies |
10/14/2014 | US8858930 Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic Escherichia coli in cattle |
10/14/2014 | US8858927 Method for protection of peptides or proteins against non-enzymatic deamidation |
10/14/2014 | US8858912 Frozen compositions and methods for piercing a substrate |
10/09/2014 | WO2014165771A2 Anti-il-4 antibodies and bispecific antibodies and uses thereof |
10/09/2014 | WO2014165728A1 Particles having peg-ylated surfaces modified for lymphatic trafficking |
10/09/2014 | WO2014165679A1 Novel nanoparticle compositions |
10/09/2014 | WO2014165677A1 Expression of hiv inhibitors by mesenchymal stem cells |
10/09/2014 | WO2014165524A2 Methods and compositions for treating and preventing disease associated with avb8 integrin |
10/09/2014 | WO2014165482A1 Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
10/09/2014 | WO2014165291A1 Improved vaccines for human papilloma virus and methods for using the same |
10/09/2014 | WO2014165287A1 Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4 |
10/09/2014 | WO2014165280A1 Rituximab induction therapy followed by glatiramer acetate therapy |
10/09/2014 | WO2014165274A2 Methods of diagnosing, preventing, and treating drug-resistant pathogenic infections using replikin sequences |
10/09/2014 | WO2014165271A2 Tau immunotherapy |
10/09/2014 | WO2014165206A1 Methods and systems of real-time medication adherence monitoring |
10/09/2014 | WO2014165181A1 Compositions for treatment of retinal detachment |
10/09/2014 | WO2014165164A2 Compositions and methods for treating autoimmune diseases |
10/09/2014 | WO2014165119A1 Cyclodextrin and antibody-drug conjugate formulations |
10/09/2014 | WO2014165115A1 Humanized anti-n2 antibodies |
10/09/2014 | WO2014165103A1 Individualized high-purity glioblastoma multiforme stem cells and methods for stimulating immune response |
10/09/2014 | WO2014165101A1 Individualized high purity colon carcinoma stem cells, methods and use of the same |
10/09/2014 | WO2014165082A2 Antibodies and methods of detection |
10/09/2014 | WO2014165028A1 Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases |
10/09/2014 | WO2014164913A1 Compositions and methods for inducing apoptosis |
10/09/2014 | WO2014164727A1 A method of treating fungal infection |
10/09/2014 | WO2014164709A2 Engineered anti-tgf-beta antibodies and antigen-binding fragments |
10/09/2014 | WO2014164699A1 Herpes virus vaccines and treatments |
10/09/2014 | WO2014164697A1 Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
10/09/2014 | WO2014164680A1 Cd20-binding immunotoxins for inducing cellular internalization and methods using same |
10/09/2014 | WO2014164607A1 Vibro-based delivery system and immune suppression |
10/09/2014 | WO2014164553A1 Antigen binding constructs to cd8 |
10/09/2014 | WO2014164534A2 Site-specific antibody-drug conjugation through glycoengineering |
10/09/2014 | WO2014164464A1 High purity ovarian cancer stem cells for active autologous immune therapy |
10/09/2014 | WO2014164067A1 Antigen binding constructs to cd30 |
10/09/2014 | WO2014164055A1 Global gene regulators (ggr) as vaccine candidates against paratuberculosis |
10/09/2014 | WO2014163684A1 Combination therapy for inducing immune response to disease |
10/09/2014 | WO2014163257A1 Novel infectious bursal disease (ibd) virus k7 strain and vaccine against infectious bursal disease using same |
10/09/2014 | WO2014163213A1 Anti-tumor dna vaccine |
10/09/2014 | WO2014163101A1 Fc region variant |
10/09/2014 | WO2014162962A1 Tumor antigen peptide |
10/09/2014 | WO2014162102A1 Novel mycobacterium tuberculosis target and use thereof in the screening of anti-tuberculosis drugs |
10/09/2014 | WO2014162036A1 Immunogenic complex for vaccination and method for the production thereof |
10/09/2014 | WO2014162031A1 Recombinant vectors based on the modified vaccinia ankara virus (mva) as preventive and therapeutic vaccines against hepatitis c |
10/09/2014 | WO2014161887A1 Targeted cancer immune therapy |
10/09/2014 | WO2014161845A1 Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
10/09/2014 | WO2014161483A1 Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins |
10/09/2014 | WO2014161090A1 Campylobacter vaccine |
10/09/2014 | WO2014161046A1 Methods of treating diseases characterized by excessive wnt signalling |
10/09/2014 | WO2014161037A1 Antibodies against human ryk and uses therefor |
10/09/2014 | US20140303357 Liquid formulation containing a protein drug |
10/09/2014 | US20140303077 Albumin fusion proteins |
10/09/2014 | US20140302499 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors |
10/09/2014 | US20140302153 Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
10/09/2014 | US20140302124 Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION |
10/09/2014 | US20140302120 Conjugates of synthetic tlr agonists and uses therefor |
10/09/2014 | US20140302098 Yeast-based vaccines as immunotherapy |
10/09/2014 | US20140302097 Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
10/09/2014 | US20140302096 Compositions for the preparation of mature dendritic cells |
10/09/2014 | US20140302093 Microorganisms carrying a tumor antigen |
10/09/2014 | US20140302091 Methods and compositions for live attenuated viruses |
10/09/2014 | US20140302090 Novel vaccine |
10/09/2014 | US20140302089 Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
10/09/2014 | US20140302088 Compositions and methods for dengue virus chimeric constructs in vaccines |
10/09/2014 | US20140302087 Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant |
10/09/2014 | US20140302085 Use of gk-1 peptide expressed on m13 filamentous phage as pharmaceutical ingredient to enhance the efficiency of the immune response induced by vaccine or pathogen antigens |
10/09/2014 | US20140302083 Porphyromonas gingivalis polypeptides and nucleotides |
10/09/2014 | US20140302081 Hiv-1 gp120 mini v3 loop and uses thereof |
10/09/2014 | US20140302078 Haemophilus influenzae type b |
10/09/2014 | US20140302074 Pat-LM1 Epitopes and Methods for Using Same |
10/09/2014 | US20140302073 Immunogenic protein pas n 1 from bahia grass pollen |
10/09/2014 | US20140302071 Peptides for vaccine |
10/09/2014 | US20140302069 Modulators of c3a receptors |
10/09/2014 | US20140302058 Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
10/09/2014 | US20140302053 Compositions for the treatment of rheumatoid arthritis and methods of using same |
10/09/2014 | US20140302052 Combination Therapy to Enhance NK Cell Mediated Cytotoxicity |
10/09/2014 | US20140302051 Biocompatible Hydrogel Polymer Formulations for the Controlled Delivery of Biomolecules |
10/09/2014 | US20140302046 Immunological Targeting of Pathological Tau Proteins |
10/09/2014 | US20140302045 Igy composition for use in celiac disease |
10/09/2014 | US20140302040 Novel Antibodies and Uses Thereof |
10/09/2014 | US20140302039 Combination therapy using anti-c-met antibody and anti-ang-2 antibody |
10/09/2014 | US20140302036 Proteins specific for baff and b7rp1 |
10/09/2014 | US20140302032 Monoclonal antibodies for tumor treatment |
10/09/2014 | US20140302030 Method of combination therapy using anti-c-met antibody and sorafenib |
10/09/2014 | US20140302023 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging |
10/09/2014 | US20140302021 Antibody formulations and methods |
10/09/2014 | US20140302020 Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |